SIREN : 533049086
BB FARMA is a French company founded 14 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. this company of category PME shows in 2016 a revenue of 3.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2016 | 2015 |
|---|---|---|
| Revenue | 3 427 267 € | 2 242 851 € |
| Net income | 224 107 € | 277 138 € |
| EBITDA | 348 231 € | 289 524 € |
| Net margin | 6.5% | 12.4% |
In 2016, BB FARMA achieves revenue of 3.4 M€. Vs 2015, growth of +53% (2.2 M€ -> 3.4 M€). After deducting consumption (2.5 M€), gross margin stands at 908 k€, i.e. a rate of 27%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 348 k€, representing 10.2% of revenue. Warning negative scissor effect: despite revenue change (+53%), EBITDA varies by +20%, reducing margin by 2.7 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 224 k€, i.e. 6.5% of revenue. This profit can be retained or distributed to shareholders.
3 427 267 €
908 457 €
348 231 €
333 693 €
224 107 €
10.2%
The debt ratio (= Financial debt / Equity x 100) stands at 443%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 14%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 7.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
443.427%
13.858%
6.995%
4.145
39.5%
In 2016, the debt ratio of BB FARMA (443.43) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2016, the financial autonomy of BB FARMA (13.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2016, the repayment capacity of BB FARMA (4.14) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 403.24. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
403.243
0.0
In 2016, the liquidity ratio of BB FARMA (403.24) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2016, the interest coverage of BB FARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 123 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 28 days. The gap of 95 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 36 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 147 days of revenue, i.e. 1.4 M€ to permanently finance.
1 395 172 €
123 j
28 j
36 j
147 j
Based on 124 transactions of similar company sales (all years), the value of BB FARMA is estimated at 378 354 € (range 190 697€ - 1 243 813€). With an EBITDA of 348 231€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BB FARMA with other companies in the same sector:
The revenue of BB FARMA in 2016 is 3.4 M€.
Yes, BB FARMA generated a net profit of 224 k€ in 2016.
The headquarters of BB FARMA is located in address not disclosed.
The tax return of BB FARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BB FARMA operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.